Journal of Korean Foot and Ankle Society (대한족부족관절학회지)

Korean Foot & Ankle Society (대한족부족관절학회)
권호 표지
DOI QR코드

DOI QR Code

Effects of Beraprost Sodium Evaluated by Digital Infrared Thermal Imaging in Diabetic Patients with Peripheral Arterial Disease

당뇨병성 말초혈관병증 환자에게 Beraprost Sodium이 미치는 영향에 대한 적외선 체열검사를 통한 연구

  • Park, Hyun Woo (Department of Orthopedic Surgery, Dankook University College of Medicine) ;
  • Soh, Jae Wan (Department of Orthopedic Surgery, Soonchunhyang University Cheonan Hospital, Soonchunhyang University College of Medicine) ;
  • Park, Seong Hyeon (Department of Orthopedic Surgery, Daejeon St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Jeong, Jae Jung (Department of Orthopedic Surgery, Daejeon St. Mary's Hospital, College of Medicine, The Catholic University of Korea)
  • 박현우 (단국대학교 의과대학 정형외과학교실) ;
  • 소재완 (순천향대학교 의과대학 천안병원 정형외과학교실) ;
  • 박성현 (가톨릭대학교 의과대학 대전성모병원 정형외과학교실) ;
  • 정재중 (가톨릭대학교 의과대학 대전성모병원 정형외과학교실)
  • Received : 2018.07.10
  • Accepted : 2018.08.13
  • Published : 2018.09.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: This study examined the effects of beraprost sodium on digital infrared thermal images in patients with peripheral arterial disease caused by type 2 diabetes mellitus. Materials and Methods: Twenty-five diabetic patients with peripheral arterial disease were treated with beraprost sodium in a prospective, multicenter, cohort study from February 2013 to December 2014. Beraprost sodium ($40{\mu}g$) was administered orally 3 times daily ($120{\mu}g/day$) for 6 months. The visual analogue scale (VAS) and digital infrared thermal imaging (DITI) were performed to compare the blood flow improvement between before and after dosing. Results: Among the 25 patients included in the evaluation, 22 patients completed the study. A significant increase in body temperature was observed in the front and left side, particularly in the plantar side in DITI compared to that before and after administration. An increase in body temperature was observed at the frontal part from $28.1^{\circ}C{\pm}2.3^{\circ}C$ to $29.1^{\circ}C{\pm}2.1^{\circ}C$ (p=0.021), at the left side from $27.8^{\circ}C{\pm}2.4^{\circ}C$ to $28.6^{\circ}C{\pm}1.9^{\circ}C$ (p=0.028), at the plantar part at $24.0^{\circ}C{\pm}1.5^{\circ}C$, and at the plantar part at $27.1^{\circ}C{\pm}2.4^{\circ}C$ (p<0.01). The VAS decreased significantly from $5.4{\pm}1.3$ to $2.7{\pm}2.0$ after 6 months of treatment (p<0.01). Conclusion: Beraprost sodium is a safe and easy-to use oral medication for diabetes peripheral arterial disease. It can be expected to increase the blood flow and decrease the lower extremity pain statistically after being taken for 6 months.

Keywords

References

  1. Diabetes fact sheet in Korea 2016 [Internet]. Seoul: Korean Diabetes Association [cited 2018 Jun 2]. Available from: http://www.diabetes.or.kr/pro/news/.
  2. Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA. 2005;293:217-28. https://doi.org/10.1001/jama.293.2.217
  3. Lipsky BA, Weigelt JA, Sun X, Johannes RS, Derby KG, Tabak YP. Developing and validating a risk score for lower-extremity amputation in patients hospitalized for a diabetic foot infection. Diabetes Care. 2011;34:1695-700. https://doi.org/10.2337/dc11-0331
  4. Yoon HS, Choi WJ, Sung IH, Lee HS, Chung HJ, Lee JW. Effects of beraprost sodium on subjective symptoms in diabetic patients with peripheral arterial disease. Clin Orthop Surg. 2013;5:145-51. https://doi.org/10.4055/cios.2013.5.2.145
  5. Demolis JL, Robert A, Mouren M, Funck-Brentano C, Jaillon P. Pharmacokinetics and platelet antiaggregating effects of beraprost, an oral stable prostacyclin analogue, in healthy volunteers. J Cardiovasc Pharmacol. 1993;22:711-6. https://doi.org/10.1097/00005344-199311000-00007
  6. Lievre M, Morand S, Besse B, Fiessinger JN, Boissel JP. Oral beraprost sodium, a prostaglandin I(2) analogue, for intermittent claudication: a double-blind, randomized, multicenter controlled trial. Beraprost et Claudication Intermettente (BERCI) research group. Circulation. 2000;102:426-31. https://doi.org/10.1161/01.CIR.102.4.426
  7. Nony P, Ffrench P, Girard P, Delair S, Azoulay S, Girre JP, et al. Platelet-aggregation inhibition and hemodynamic effects of beraprost sodium, a new oral prostacyclin derivative: a study in healthy male subjects. Can J Physiol Pharmacol. 1996;74:887-93. https://doi.org/10.1139/y96-088
  8. Uchikawa T, Murakami T, Furukawa H. Effects of the anti-platelet agent cilostazol on peripheral vascular disease in patients with diabetes mellitus. Arzneimittelforschung. 1992;42:322-4.
  9. Beebe HG, Dawson DL, Cutler BS, Herd JA, Strandness DE Jr, Bortey EB, et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med. 1999;159:2041-50. https://doi.org/10.1001/archinte.159.17.2041
  10. Dawson DL, Cutler BS, Hiatt WR, Hobson RW 2nd, Martin JD, Bortey EB, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med. 2000;109:523-30. https://doi.org/10.1016/S0002-9343(00)00569-6
  11. Dawson DL, Cutler BS, Meissner MH, Strandness DE Jr. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation. 1998;98:678-86. https://doi.org/10.1161/01.CIR.98.7.678
  12. Marso SP, Hiatt WR. Peripheral arterial disease in patients with diabetes. J Am Coll Cardiol. 2006;47:921-9. https://doi.org/10.1016/j.jacc.2005.09.065
  13. Belch JJ, Bell PR, Creissen D, Dormandy JA, Kester RC, McCollum RD, et al. Randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of AS-013, a prostaglandin E1 prodrug, in patients with intermittent claudication. Circulation. 1997;95:2298-302. https://doi.org/10.1161/01.CIR.95.9.2298
  14. Muller-Buhl U, Diehm C, Krais T, Zimmermann R, Morl H, Eckstein HH. Clinical effects of intravenous iloprost in patients with intermittent claudication. Eur J Clin Pharmocol. 1987;33:127-31. https://doi.org/10.1007/BF00544555
  15. Friedman R, Mears JG, Barst RJ. Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension. Circulation. 1997;96:2782-4. https://doi.org/10.1161/01.CIR.96.9.2782
  16. Vane JR, Botting RM. Pharmacodynamic profile of prostacyclin. Am J Cardiol. 1995;75:3A-10A. https://doi.org/10.1016/S0002-9149(99)80377-4
  17. Goya K, Otsuki M, Xu X, Kasayama S. Effects of the prostaglandin I2 analogue, beraprost sodium, on vascular cell adhesion molecule-1 expression in human vascular endothelial cells and circulating vascular cell adhesion molecule-1 level in patients with type 2 diabetes mellitus. Metabolism. 2003;52:192-8. https://doi.org/10.1053/meta.2003.50025
  18. Galie N, Manes A, Branzi A. Prostanoids for pulmonary arterial hypertension. Am J Respir Med. 2003;2:123-37. https://doi.org/10.1007/BF03256644
  19. Ueno Y, Koike H, Nakamura Y, Ochi Y, Annoh S, Nishio S. Effects of beraprost sodium, a prostacyclin analogue, on diabetic neuropathy in streptozotocin- induced diabetic rats. Jpn J Pharmacol. 1996;70:177-82. https://doi.org/10.1254/jjp.70.177
  20. Aso Y, Tayama K, Takanashi K, Inukai T, Takemura Y. Changes in skin blood flow in type 2 diabetes induced by prostacyclin: association with ankle brachial index and plasma throbomodulin levels. Metabolism. 2001;50:568-72. https://doi.org/10.1053/meta.2001.22517